Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

cent in this year's second quarter to $34.8 million from $25.1 million in the same quarter a year ago. This growth is being driven by the expanded U.S. sales force for Seprafilm(R) adhesion barrier, which is helping to expand the product's use in gynecologic and colorectal surgery and C-section procedures.

Second-quarter revenue for the Genetics business increased 7 percent to $78.5 million from $73.7 million. This growth was driven in part by the continuing demand for prenatal screening for genetic conditions. Additionally, Genzyme experienced increased demand for its KRAS mutation testing for colorectal cancer, as recent studies have shown that identifying KRAS mutations can assist oncologists in selecting treatment for patients with colorectal cancer. This increasing recognition of the value of diagnostics in personalized medicine will continue to fuel organic growth in the Genetics business.

Oncology revenue rose in the second quarter to $33.3 million from $17.4 million based on increasing sales of Clolar and Campath(R) (alemtuzumab). The increase also reflects the addition of European sales of Clolar, which Genzyme began recording following its acquisition of Bioenvision Inc. late last year. Genzyme is working to introduce Clolar worldwide as well as expand its indications. The product is currently approved in the United States and Europe as a third-line treatment for pediatric patients with acute lymphoblastic leukemia. Genzyme is developing Clolar for use globally as a first-line therapy for adult AML and myelodysplastic syndromes, significantly larger indications that the company estimates will drive peak annual sales of the product to approximately $600 million. Last month, Genzyme reported encouraging results from its pivotal CLASSIC II trial evaluating the use of Clolar to treat older adult patients with acute myeloid leukemia. Oncology revenue also reflects growing first-line use of Campath in the treatment of patients with B-cell chronic l
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  ECC West Africa, LLC (ECC) ... with University College Hospital (UCH) Ibadan Board of ... to finance, design, construct, and operate and maintain a ... . Under the first of the 4-phase project, ... and funding applications. UCH Ibadan intends to finance and ...
(Date:7/24/2014)... materialise. Yet, scientists are making progress in devising ... such approach relies on quantum dotsa kind of ... field. A new study demonstrates that changing the ... with electrical impulses can help better control them. ... used as quantum information units, which would produce ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Cell Culture Market 2014-2018" report to their ... Cell culture is the in vitro growth of ... research, cell studies, and biopharmaceutical production. Cell culture is ... Cell culture instruments and cell culture consumables are necessary ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... professor of materials science and engineering at Virginia ... the Friedrich Wilhelm Bessel Research Award presented by ... is for scholars, internationally renowned in their field, ... ago and who are expected to continue to ...
... Investor Uprising ( www.investoruprising.com ) has released "A Guide ... best biotech Exchange Traded Funds (ETFs) and mutual funds, ... Website. (Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a) "A ... market, identifying the leading biotech mutual funds and ETFs. ...
... 2011 Aaron Mitchell, managing principal at global management consulting ... consultants of 2011 by Consulting Magazine. Mitchell was recognized for ... over several years and during a major, recent product launch. ... the top consultants," said Mitchell, who has more than 10 ...
Cached Biology Technology:Virginia Tech's Kathy Lu receives Humboldt Foundation research award 2Investor Uprising Publishes Free Biotech Investment Report 2Investor Uprising Publishes Free Biotech Investment Report 3Managing Principal at ZS Associates Named One of Consulting Magazine's Top 25 Consultants of 2011 2
(Date:7/24/2014)... is available in German . ... Norway and they are a common sight on the roads ... cars topped the list of new vehicle registrations for the ... in Germany, where electric vehicles claim only a small portion ... roads in Germany, only a mere 8000 are electric powered. ...
(Date:7/24/2014)... a virus living inside your gut that has gone ... by researchers at San Diego State University has found ... to a newly described virus, named crAssphage, which infects ... Bacteroidetes . This phylum of bacteria is thought ... diseases. The research appears today in Nature Communications ...
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today ... the University of Massachusetts Amherst School of Public ... three-year, $700,000 Science to Achieve Results (STAR) grant ... by Native subsistence hunters in subarctic North America ... exposure and to provide culturally-relevant recommendations for mitigation. ...
Breaking Biology News(10 mins):Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3
... is underway that hopes to use a patient's own immune ... immunotherapy, is a specialty procedure performed in only a handful ... Medical Center. , Julian A. Kim, M.D., chief of surgical ... grant from the National Institutes of Health for a five-year ...
... 12 surgeons and 21 surgical residents, video game skill ... a simulated surgery skills course, according to a report ... of the JAMA/Archives journals. , James C. Rosser Jr., ... colleagues asked 33 surgeons (21 residents and 12 attending ...
... new study has pinpointed a natural ingredient of human ... for human AIDS, from infecting immune cells and multiplying. ... progression of HIV to full-blown AIDS and—because it works ... to the development of another class of drugs in ...
Cached Biology News:Discovery of an HIV inhibitor in human blood points to new drug class 2Discovery of an HIV inhibitor in human blood points to new drug class 3